371 related articles for article (PubMed ID: 34988773)
1. Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: a propensity score matching.
Hong ZN; Zhang Z; Chen Z; Weng K; Peng K; Lin J; Kang M
Esophagus; 2022 Apr; 19(2):224-232. PubMed ID: 34988773
[TBL] [Abstract][Full Text] [Related]
2. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
Front Immunol; 2022; 13():836338. PubMed ID: 35300335
[TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.
Sihag S; Ku GY; Tan KS; Nussenzweig S; Wu A; Janjigian YY; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2021 Mar; 161(3):836-843.e1. PubMed ID: 33485662
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study.
Hong ZN; Weng K; Peng K; Chen Z; Lin J; Kang M
Front Oncol; 2021; 11():797426. PubMed ID: 34970498
[TBL] [Abstract][Full Text] [Related]
5. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study.
Hong Z; Xu J; Chen Z; Xu H; Huang Z; Weng K; Cai J; Ke S; Chen S; Xie J; Duan H; Kang M
Int J Surg; 2023 Aug; 109(8):2168-2178. PubMed ID: 37318861
[TBL] [Abstract][Full Text] [Related]
6. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.
Wang K; Liang Y; Huang J; Xie X; Wu D; Chen B; Wang K; Shen Z; Li Y; Wang W; Hu X; Wang M
J Surg Oncol; 2023 Aug; 128(2):207-217. PubMed ID: 37036218
[TBL] [Abstract][Full Text] [Related]
7. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
Front Immunol; 2022; 13():970534. PubMed ID: 36275724
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
9. Robot-assisted versus video-assisted thoraco-laparoscopic McKeown's esophagectomy for esophageal cancer: a propensity score-matched analysis of minimally invasive approaches.
Kulkarni A; Mulchandani JG; Sadat MS; Shetty N; Shetty S; Kumar MP; Kudari A
J Robot Surg; 2022 Dec; 16(6):1289-1297. PubMed ID: 35044671
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
11. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Recurrence and Long-Term Survival of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Locally Advanced Esophageal Cancer Treated with Neoadjuvant Chemotherapy: a Propensity Score-Matched Analysis.
Sugimura K; Miyata H; Kanemura T; Takeoka T; Sugase T; Masuzawa T; Katsuyama S; Motoori M; Takeda Y; Murata K; Yano M
J Gastrointest Surg; 2023 Jun; 27(6):1055-1065. PubMed ID: 36749557
[TBL] [Abstract][Full Text] [Related]
13. Propensity Score-Matched Analysis Comparing Minimally Invasive Ivor Lewis Versus Minimally Invasive Mckeown Esophagectomy.
van Workum F; Slaman AE; van Berge Henegouwen MI; Gisbertz SS; Kouwenhoven EA; van Det MJ; van den Wildenberg FJH; Polat F; Luyer MDP; Nieuwenhuijzen GAP; Rosman C
Ann Surg; 2020 Jan; 271(1):128-133. PubMed ID: 30102633
[TBL] [Abstract][Full Text] [Related]
14. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis.
Plum PS; Damanakis A; Buschmann L; Ernst A; Datta RR; Schiffmann LM; Zander T; Fuchs H; Chon SH; Alakus H; Schröder W; Hölscher AH; Bruns CJ; Bludau M
J Cancer Res Clin Oncol; 2022 May; 148(5):1223-1234. PubMed ID: 34223965
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application and analysis of single-port laparoscopic and thoracoscopic McKeown esophagectomy for esophageal cancer].
Liu B; Qiu ML; Feng Z; Lin NL; Yu MJ; Li X
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(29):2316-2321. PubMed ID: 34333948
[No Abstract] [Full Text] [Related]
17. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).
Zhang Z; Hong ZN; Xie S; Lin W; Lin Y; Zhu J; Yang X; Lin Z; Lin J; Kang M
Ann Transl Med; 2021 Nov; 9(21):1623. PubMed ID: 34926667
[TBL] [Abstract][Full Text] [Related]
18. Safety and feasibility of minimally invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer: a propensity score-matched analysis in China.
Cui H; Liang W; Cui J; Song L; Yuan Z; Chen L; Wei B
Gastroenterol Rep (Oxf); 2024; 12():goae005. PubMed ID: 38425656
[TBL] [Abstract][Full Text] [Related]
19. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer.
Yamashita K; Makino T; Yamasaki M; Tanaka K; Hara T; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Dis Esophagus; 2017 Nov; 30(11):1-8. PubMed ID: 28881906
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.
Zhao J; Hao S; Tian J; Li Y; Han D
J Inflamm Res; 2023; 16():3351-3363. PubMed ID: 37576156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
